Rocbrutinib

Rocbrutinib (NWP-775, LP-168) is a small-molecule drug developed by Guangzhou Lupeng Pharmaceutical and Newave Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: 200mg qd PO. The treatment will continue until progressive disease, unacceptable toxicity, etc. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07377578 (A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma) and NCT07342478 (ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL), in mantle cell lymphoma, chronic lymphocytic leukaemia and diffuse large B-cell lymphoma. The largest, NCT07377578, plans to enrol 394 participants with primary completion expected 2031-05-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.